Design Therapeutics reports Q2 EPS (34c), consensus (33c)

“We’ve made meaningful progress across our pipeline this quarter,” said Pratik Shah, chairperson and chief executive officer of Design Therapeutics (DSGN). “Early human PK data for DT-216P2 demonstrate the consistency of human plasma exposure profiles with NHP data across both IV and subcutaneous routes. We’re also pleased to have initiated our Phase 2 biomarker trial in patients with FECD, a disease with no approved disease-modifying therapies. Our preclinical programs also continue to advance as we work to deliver a new class of genomic medicines for patients with serious degenerative diseases.”